Physician profile
Eric Lee
NPI 1760481808
$12,733.98
in general payments reported to CMS, 2019-2025
39 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,954 · 2020: $2,793 · 2021: $1,123 · 2022: $791 · 2023: $790 · 2024: $2,085 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,071.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,824.85 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Ucb, INC. | $1,725.25 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,408.98 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,349.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $882.92 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $744.03 | 2019-2025 | |
| Pfizer INC. | $741.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $669.10 | 2019-2023 | Orencia |
| US Oncology Corporate, INC. | $621.58 | 2024 | |
| Genentech USA, INC. | $419.73 | 2019-2021 | |
| Horizon Therapeutics Plc | $363.88 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $316.46 | 2022-2024 | Saphnelo |
| Celgene Corporation | $216.52 | 2019-2020 | |
| Radius Health, INC. | $190.16 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $173.61 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $131.95 | 2020-2024 | Acthar |
| Sobi, INC | $130.98 | 2019-2020 | |
| Genzyme Corporation | $129.62 | 2019 | |
| Lilly USA, LLC | $127.43 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $115.63 | 2021-2023 | Lupkynis |
| Gilead Sciences, INC. | $101.91 | 2019-2020 | |
| Organon LLC | $99.08 | 2022-2025 | Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.45 | 2020-2024 | Ofev |
| Medexus Pharma, INC. | $57.75 | 2019 | |
| Depuy Synthes Sales INC. | $34.63 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $23.64 | 2024 | Arcalyst |
| Almatica Pharma LLC | $21.71 | 2025 | Loreev Xr |
| Sanofi-Aventis U.S. LLC | $20.36 | 2019 | |
| Siemens Medical Solutions USA, INC. | $13.21 | 2024 | Magnetom Altea |
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.